According to a study conducted by BioAsia along with knowledge partner Deloitte, the financial year 2016-2017 has been among the toughest years for the Indian Pharma companies due to frequent foreign regulatory interventions and major domestic structural policy initiatives. It has been noted that ...
Read more: BioAsia to focus on regulatory challenges in pharma